Jun 08, 2023 / 01:00PM GMT
Akash Tewari - Jefferies LLC, Research Division - Equity Analyst
All right. Good morning, everyone. Thank you for joining us Day 2 of the Jefferies Healthcare Conference here in beautiful Times Square. I -- for those who don't know me, my name is Akash Tewari. I'm a pharma and biotech analyst here at Jefferies, and I have the pleasure of hosting Bristol and the new Chief Commercialization Officer, Adam Lenkowsky, who is going to join us for a fire-side chat.
Questions and Answers:
Akash Tewari - Jefferies LLC, Research Division - Equity AnalystI think, Adam, maybe just to start off as we get into Q&A, it's funny. If you always -- I always read pharma transcripts from 5 years ago or slide decks from companies and whatever seems to be the biggest debate that everyone's convinced is going to drive the stock over the next 5 years, never ends up actually because it was important. And you come into this role, this is a company where the new product launches are just so critical. And I feel like the way Wall Street looks at everything it's so binary, right?